Occam Places Prominent Scientific Leader at High Profile Neuro Startup
In October 2024, Occam recruited Laurens Kruidenier, PhD, as CSO of Nilo Therapeutics, a New York City based biotech backed by a blue chip syndicate.
Laurens joins Nilo from Cellarity, a Flagship investment employing an algorithmic, target-agnostic approach to drug discovery, where he served as CSO.
His first CSO role came at Prometheus Biosciences, an immunology play that sold to Merck for ~$11BN in 2023. Laurens began his industrial career at GSK.
About Nilo Therapeutics
Co-founded by Charles Zuker, Ruslan Medzhitov, and Steve Liberles, Nilo Therapeutics is an NYC-based biotech founded on seminal research revealing the ability to regulate human immune response via activation of neural circuits. The company is developing a pipeline of therapeutics for autoimmune and inflammatory indications.
In late 2024, Nilo raised a $101M Series A from The Column Group, DCVC Bio and Lux Capital.
Recent Placements
Occam Global is a trusted executive search, consulting, and investment partner for leaders and investors shaping the future of life sciences, deep tech, and venture capital. Since 2012, we’ve helped build high-performing teams and advised visionary companies from stealth to public markets. Our success stems from exceptional access to rare talent, deep sector expertise, and a commitment to results guided by elevated ethics and enlightened aggression.